IMMUNOLOGY2026™ Conference Recordings For Attendees-Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development, Sponsored by Breakthrough T1D-2

Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development, Sponsored by Breakthrough T1D-2

Video Transcription

Video Summary

Erin Maul described developing IL-2-conjugated lipid nanoparticles (LNPs) to deliver mRNA specifically to regulatory T cells (Tregs) for autoimmune therapy, especially type 1 diabetes. She compared IL-2 targeting with anti-CD25 antibody targeting and found IL-2 LNPs were more effective and selective in mice and human cells. The system showed strong Treg uptake, limited off-target delivery, reduced liver accumulation, and signs of IL-2 receptor signaling. This approach could avoid laborious ex vivo Treg engineering and may be adapted to deliver cargos that improve Treg function and pancreatic homing.

Meta Tag

Date April 16, 2026 7:00 AM - 8:00 AM

Room 151

Session Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development

Speaker Erin Maule

Track Basic Autoimmunity (BA)

Year 2026

Keywords

IL-2-conjugated lipid nanoparticles

regulatory T cells

autoimmune therapy

type 1 diabetes

Treg targeting

April 16, 2026 7:00 AM - 8:00 AM

151

Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development

Erin Maule

Basic Autoimmunity (BA)

2026